StrongBox Wealth LLC Acquires 42 Shares of Amgen Inc. (NASDAQ:AMGN)

StrongBox Wealth LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,649 shares of the medical research company’s stock after buying an additional 42 shares during the quarter. Amgen accounts for about 1.3% of StrongBox Wealth LLC’s holdings, making the stock its 27th biggest holding. StrongBox Wealth LLC’s holdings in Amgen were worth $3,036,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Flywheel Private Wealth LLC acquired a new position in Amgen in the 4th quarter worth about $340,000. Rovin Capital UT ADV increased its holdings in Amgen by 89.1% in the 4th quarter. Rovin Capital UT ADV now owns 1,235 shares of the medical research company’s stock worth $322,000 after purchasing an additional 582 shares in the last quarter. Smith Thornton Advisors LLC increased its holdings in Amgen by 53.3% in the 4th quarter. Smith Thornton Advisors LLC now owns 1,185 shares of the medical research company’s stock worth $309,000 after purchasing an additional 412 shares in the last quarter. Sawyer & Company Inc increased its stake in shares of Amgen by 0.4% in the fourth quarter. Sawyer & Company Inc now owns 15,996 shares of the medical research company’s stock valued at $4,169,000 after buying an additional 57 shares during the period. Finally, Pinnacle Bancorp Inc. increased its stake in shares of Amgen by 38.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 737 shares of the medical research company’s stock valued at $192,000 after buying an additional 205 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.7 %

NASDAQ:AMGN opened at $268.94 on Thursday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The firm has a 50-day moving average of $277.12 and a 200-day moving average of $308.03. The company has a market cap of $144.56 billion, a PE ratio of 34.44, a PEG ratio of 2.91 and a beta of 0.56. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the firm posted $4.96 earnings per share. As a group, equities research analysts expect that Amgen Inc. will post 19.53 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.54%. Amgen’s payout ratio is presently 121.90%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on AMGN shares. William Blair reissued an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Sanford C. Bernstein started coverage on Amgen in a research note on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target for the company. Redburn Partners decreased their price target on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Piper Sandler decreased their price target on Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. Finally, Citigroup decreased their price target on Amgen from $335.00 to $310.00 in a research note on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.